Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Arthritis Research UK has approved a 5-year renewal of the OA Centre.

The Arthritis Research UK Centre for Osteoarthritis (OA) Pathogenesis was first established in 2013 to identify new targets in the disease and create a seamless pipeline between laboratory discovery and clinical trials.

OA is the most common, yet one of the most neglected diseases of rheumatology, affecting over 8 million people in the UK. As with all diseases, it is important to understand the underlying pathways that drive the condition before drug treatments can be designed.

The Centre has had several successes in this area so far and has built an international reputation which has attracted excellent students, visiting workers and research fellows.

The Centre is delighted to receive further funding from Arthritis Research UK to continue this important work. Professor Tonia Vincent, Director of the Centre said:

"This grant has given us the opportunity to contribute to international efforts to understand early molecular pathways in OA. We are now in a position to move these forward to assess their suitability as targets in human disease. The next 5 years will be an exciting time for all of us and, we hope, a cause for optimism for our millions of OA sufferers."

Over the next five years, the Centre will focus its efforts in select areas of the disease, such as how tissues of the joint respond to injury, and on those areas where the Centre can expect to have the biggest impact, such as discovering new ways to image early damage in OA joints.

Although large scale clinical trials are still a little way off, the Centre believes that by the end of this grant, it will have tested two or three targets in groups of OA patients.

Similar stories

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Wellcome Trust Investigator Award for Professor Arnon

Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”

Oxford researchers awarded funding to study the immune response to malaria

Professors Matthew Higgins and Michael Dustin from the University of Oxford, Prof Gavin Wright from the University of York, and Professors Shiroh Iwanaga and Hisashi Arase from Osaka University have secured a Wellcome Collaborative Award for their study “How do RIFINs and STEVORs modulate human immunity during malaria?”

New funding awarded to study persistent pain in inflammatory arthritis

The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.